{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:56:38Z","timestamp":1793148998433,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.diabres.2020.108487","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:15:31Z","timestamp":1601982931000},"page":"108487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial"],"prefix":"10.1016","volume":"170","author":[{"given":"Wen","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diabres.2020.108487_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.28524","article-title":"The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health[J]","volume":"64","author":"Rinella","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2020.108487_b0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a system-atic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108487_b0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabres.2020.108487_b0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.diabres.2020.108487_b0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1440-1746.2010.06528.x","article-title":"Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease","volume":"26","author":"Manchanayake","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2020.108487_b0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.diabres.2020.108487_b0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2020.108487_b0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 basedtherapies: clinical implications for gastroenterologists","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2020.108487_b0045","first-page":"1","article-title":"Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4\/NF-kB inflammatory pathway and oxidative stress in T2DM\/NAFLD rats.[J].Tissue and","author":"Xiangjin","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.diabres.2020.108487_b0050","article-title":"High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program[J]","author":"Armstrong","year":"2010","journal-title":"Indian Country Today"},{"key":"10.1016\/j.diabres.2020.108487_b0055","doi-asserted-by":"crossref","unstructured":"Bizino Maurice B, Jazet Ingrid M, de Heer Paul et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.[J] .Diabetologia, 2020, 63: 65-74. https:\/\/doi.org\/10.1007\/s00125-019-05021-6.","DOI":"10.1007\/s00125-019-05021-6"},{"key":"10.1016\/j.diabres.2020.108487_b0060","doi-asserted-by":"crossref","first-page":"e3292","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Lin","year":"2020","journal-title":"Diabet Metab Res Rev"},{"key":"10.1016\/j.diabres.2020.108487_b0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"End-points and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.diabres.2020.108487_b0070","first-page":"60","article-title":"Multiparametric magnetic reso-nance for the non-invasive diagnosis of liver disease","author":"Banerjee","year":"2014","journal-title":"J Hepat0ol"},{"key":"10.1016\/j.diabres.2020.108487_b0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2012.128","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"107","author":"Naga","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.diabres.2020.108487_b0080","doi-asserted-by":"crossref","unstructured":"Cuthbertson Daniel J, Irwin Andrew, Gardner Chris J et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.[J] .PLoS ONE, 2012, 7: e50117. https:\/\/doi.org\/10.1371\/journal.pone.0050117.","DOI":"10.1371\/journal.pone.0050117"},{"key":"10.1016\/j.diabres.2020.108487_b0085","doi-asserted-by":"crossref","unstructured":"Yan Jinhua,Yao Bin,Kuang Hongyu et al. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.[J] .Hepatology, 2019, 69: 2414-2426. https:\/\/doi.org\/10.1002\/hep.30320.","DOI":"10.1002\/hep.30320"},{"key":"10.1016\/j.diabres.2020.108487_b0090","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: A randomized trial","volume":"38","author":"Tang","year":"2015","journal-title":"Diabet Care"},{"issue":"5","key":"10.1016\/j.diabres.2020.108487_b0095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabet Care"},{"key":"10.1016\/j.diabres.2020.108487_b0100","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.diabres.2020.108487_b0105","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1080\/14656566.2018.1531126","article-title":"Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease","volume":"19","author":"Raschi","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.diabres.2020.108487_b0110","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12120","article-title":"GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK","volume":"33","author":"Zhang","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.diabres.2020.108487_b0115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2147\/DMSO.S206867","article-title":"Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2\/PI3K\/Akt signaling pathway","volume":"12","author":"Pijian","year":"2019","journal-title":"Diabet Metab Syndr Obes"},{"key":"10.1016\/j.diabres.2020.108487_b0120","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2020.108487_b0125","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2020.108487_b0130","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.diabres.2020.108487_b0135","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet","volume":"302","author":"Mells","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.diabres.2020.108487_b0140","doi-asserted-by":"crossref","unstructured":"Petit Jean-Michel, Cercueil Jean-Pierre, Loffroy Romaric et al. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.[J] .J. Clin. Endocrinol. Metab., 2017, 102: 407-415. https:\/\/doi.org\/10.1210\/jc.2016-2775","DOI":"10.1210\/jc.2016-2775"},{"issue":"2","key":"10.1016\/j.diabres.2020.108487_b0145","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle mod-ification significantly reduces features of nonalcoholic steatohe-patitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2020.108487_b0150","doi-asserted-by":"crossref","unstructured":"Petit JM, Verges B. GLP-1 receptor agonists in NAFLD. Diabetes Metab. 2017;43(suppl 1):2S28-2S33. https:\/\/doi.org\/10.1016\/S1262-3636(17)30070-8.","DOI":"10.1016\/S1262-3636(17)30070-8"},{"key":"10.1016\/j.diabres.2020.108487_b0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study","volume":"21","author":"Niina","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2020.108487_b0160","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabres.2020.108487_b0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2007.02.005","article-title":"Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes","volume":"21","author":"Lingvay","year":"2007","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.diabres.2020.108487_b0170","doi-asserted-by":"crossref","unstructured":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-1402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10.1016\/j.diabres.2020.108487_b0180","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dom.12674","article-title":"Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial","volume":"18","author":"Zang","year":"2016","journal-title":"Diabet Obes Metab"},{"key":"10.1016\/j.diabres.2020.108487_b0185","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Bernard","year":"2009","journal-title":"Diabet Care"},{"key":"10.1016\/j.diabres.2020.108487_b0190","doi-asserted-by":"crossref","unstructured":"American Diabetes Association,Standards of Medical Care in Diabetes-202015. Diabetes Care in the Hospital: .[J] .Diabetes Care, 2020, 43: S193-S202. https:\/\/doi.org\/10.2337\/dc20-S001","DOI":"10.2337\/dc20-S001"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720307403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720307403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:14:49Z","timestamp":1759173289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720307403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":37,"alternative-id":["S0168822720307403"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108487","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108487"}}